IL-17A, MCP-1, CCR-2, and ABCA1 polymorphisms in children with non-alcoholic fatty liver disease

Akbulut, Ulaş Emre; Emeksiz, Hamdi Cihan; Çitli, Şenol; Çebi, Alper Han; Korkmaz, Hatice Ayça Ata; Baki, Gaye

doi:10.1016/j.jped.2018.03.005

Cited by 7 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies ( 44 ) have found that it actively transports bile acids made by cholesterol in liver cells. Lyu ( 45 ), Liu ( 46 ), and Akbulut ( 47 ) et al. further demonstrated that ABCA1 could mediate the transport of cholesterol and phospholipids from cells to high-density lipoprotein apolipoprotein, thereby affecting the transport of liver cholesterol and inducing fatty liver disease.…”

Section: Discussionmentioning

confidence: 99%

Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

BackgroundNon-alcoholic fatty liver disease (NAFLD) is a risk factor for hepatocellular carcinoma (HCC). However, its carcinogenic mechanism is still unclear, looking for both diseases’ transcriptome levels, the same changes as we are looking for NAFLD may provide a potential mechanism of action of HCC. Thus, our study aimed to discover the coexisting pathogenic genes of NAFLD and HCC.MethodsWe performed a variance analysis with public data for both diseases. At the same time, weighted gene correlation network analysis (WGCNA) was used to find highly correlated gene modules in both diseases. The darkturquoise gene module was found to be highly correlated with both diseases. Based on the diagnosis related module genes and the differential genes of the two diseases, we constructed diagnostic and prognostic models by logistic regression, univariate Cox regression, and LASSO regression. Public datasets verified the results. Meanwhile, we built a competing endogenous RNA (ceRNA) network based on the model genes and explored the related pathways and immune correlation involved in the two diseases by using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analyses. Immunohistochemistry was used to verify the different expression of ABCC5 and TUBG1 among the normal liver, NAFLD, and HCC tissues. Sodium palmitate/sodium oleate was used to establish high-fat cell models, and Real Time Quantitative Polymerase Chain Reaction (RT-qPCR) was used to verify the messenger RNA (mRNA) expression of ABCC5 in lipidization cells.ResultsA total of 26 upregulated genes and 87 downregulated genes were found using limma package identification analysis. According to WGCNA, the darkturquoise gene module was highly correlated with the prognosis of both diseases. The coexisting genes acquired by the two groups were only three central genes, that is, ABCC5, DHODH and TUBG1. The results indicated that the diagnostic and prognostic models constructed by ABCC5 and TUBG1 genes had high accuracy in both diseases. The results of immunohistochemistry showed that ABCC5 and TUBG1 were significantly overexpressed in NAFLD and HCC tissues compared with normal liver tissues. The Oil Red O staining and triglyceride identified the successful construction of HepG2 and LO2 high-fat models using PA/OA. The results of RT-qPCR showed that the lipidization of LO2 and HepG2 increased the mRNA expression of ABCC5.ConclusionsThe gene model constructed by ABCC5 and TUBG1 has high sensibility and veracity in the diagnosis of NAFLD as well as the diagnosis and prognosis of HCC. ABCC5 and TUBG1 may play an important role in the development of NAFLD to HCC. In addition, lipidization could upregulate the mRNA expression of ABCC5 in HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Regarding cytokines, there is a study [ 65 ] that evaluated some functionally selected cytokines and chemokines prior to treatment with ipilimumab (anti-CTLA4) and six weeks afterwards. This study showed that IL-17 (interleukin 17, a pro-inflammatory molecule produced by T-helper 17 cells related to auto-immune diseases [ 66 ]) correlated significantly with the development of grade 3 diarrhea and colitis when it increased between baseline and six weeks. Pistillo et al [ 67 ] showed that a high pretreatment level of soluble CTLA4 antibody (>200 pg/mL) correlated with gastrointestinal irAEs in melanoma patients treated with ipilimumab.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

et al. 2023

View full text Add to dashboard Cite

Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously unknown to clinicians, until now. A common situation in daily practice is that a patient experiences toxicity due to this type of drug and we need to resume or rechallenge treatment after resolving the adverse event. Methods: A PubMed literature review was carried out. Results: The published data regarding the resumption or rechallenge of ICI treatment in melanoma patients is scarce and heterogeneous. Depending on the study reviewed, the recurrence incidence of grade 3–4 immune-related adverse events (irAEs) ranged from 18% to 82%. Conclusion: It is possible to resume or rechallenge, but each patient should be evaluated by a multidisciplinary team for close monitoring and assessment of the risk/benefit ratio before initiating treatment.

show abstract

Interaction BetweenAGTR1andPPARγGene Polymorphisms on the Risk of Nonalcoholic Fatty Liver Disease

Zhu

Lu²,

Yang

et al. 2019

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

IL-17A, MCP-1, CCR-2, and ABCA1 polymorphisms in children with non-alcoholic fatty liver disease

Abstract: The findings of this study suggest that there may be an association between IL-17A (-197 G/A) (rs2275913) polymorphism and non-alcoholic fatty liver disease development in obese Turkish children.

Cited by 7 publications

References 28 publications

Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma

Screening of co-pathogenic genes of non-alcoholic fatty liver disease and hepatocellular carcinoma

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

Interaction BetweenAGTR1andPPARγGene Polymorphisms on the Risk of Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About